You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

42 search results for: barrier dysfunction

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pulmonology
Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease. 
View more
Connecting the Dots from Type 2 Inflammation to Patient Perspectives
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

Type 2 Inflammation
Learn the connection between chronic type 2 inflammation, symptoms, and impact on quality of life in diseases with underlying type 2 inflammation
View more
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Pulmonology
Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
View more
The Cycle of Inflammation in Adult Asthma
interactivity

The Cycle of Inflammation in Adult Asthma

Pulmonology
Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients
View more
Role of Type 2 Inflammation Across Different Chronic Diseases
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Type 2 Inflammation
Profs. Oscar Palomares, Stephan Weidinger, Valerie Lund, and Ulrike von Arnim highlight how underlying type 2 inflammation contributes to key symptoms of inflammatory diseases across organs
View more
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Dermatology
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.
View more
Diving Below the Surface of AD: The Role of Type 2 Inflammation
expert video

Diving Below the Surface of AD: The Role of Type 2 Inflammation

Dermatology
This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.
View more
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?
videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

Dermatology
Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
View more
Type 2 Inflammation Within Skin Tissue in AD
expert video

Type 2 Inflammation Within Skin Tissue in AD

Dermatology
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.
View more
Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

Dermatology
Dr. Stephan Weidinger explains how type 2 cytokines impact the skin microbiome in AD.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Is Pediatric AD Linked to Other Allergic Diseases?
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region